First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration
Japanese Journal of Ophthalmology · 2025
DOI: 10.1007/s10384-024-01134-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Jeong Hyun Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical C…. Hauptthemen laut MEDLINE: Visual Acuity, Wet Macular Degeneration, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Hospital.
Abstract (Originalsprache)
Purpose
To investigate the first-year real-world anatomical and functional outcomes of intravitreal brolucizumab injection in eyes with refractory neovascular age-related macular degeneration (nAMD). Study design Retrospective observational study. Methods nAMD patients who showed poor response to previous anti-vascular endothelial growth factor (VEGF) agents were switched to brolucizumab. Functional and anatomical outcomes were evaluated at initial treatment of nAMD, after treatment with other anti-VEGF agents and after switching and treating with brolucizumab for 1 year. Safety profile was also evaluated after brolucizumab injection. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), and the presence of fluid in different compartments (intraretinal fluid [IRF], subretinal fluid [SRF], pigment epithelial detachment [PED]) were assessed at each time point.
Results
A total of 40 eyes of 40 patients were included in the study. BCVA remained unchanged throughout treatment ( p > 0.05). CFT did not change after treatment with other anti-VEGF agents ( p = 0.588) but decreased after switching to brolucizumab ( p < 0.001). SFCT decreased after treatment with other anti-VEGF agents ( p = 0.025) but not after switching to brolucizumab ( p = 0.236). Presence of SRF ( p = 0.001) and PED ( p = 0.001) decreased significantly after switching to brolucizumab, despite their persistence with prior treatments using other anti-VEGF agents. However, IRF persisted even after switching to brolucizumab ( p = 0.745). Intraocular inflammation (IOI)-related adverse events were reported in 3 eyes (7.14%).
Conclusion
Analysis of first-year real-world outcomes after switching to brolucizumab in nAMD patients refractory to other anti-VEGF agents showed improved anatomic outcomes, limited functional improvement and low incidence of IOI-related adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea. autre24@gmail.com.
Förderung
- Seoul National University Hospital
Zitieren
APA
Lee, J. H., Shin, J. Y., & Ahn, J. (2025). First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01134-7
Vancouver
Lee JH, Shin JY, Ahn J. First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-024-01134-7
BibTeX
@article{Lee2025,
author = {Lee, Jeong Hyun and Shin, Joo Young and Ahn, Jeeyun},
title = {First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration},
journal = {Japanese Journal of Ophthalmology},
year = {2025},
doi = {10.1007/s10384-024-01134-7}
}
EUVIMED